<DOC>
	<DOC>NCT00475956</DOC>
	<brief_summary>The purpose of the study is to determine if the maximum tolerated doses of AZD2171, in combination with AZD0530, in treating patients with advanced solid tumours are safe, tolerable and efficacious.</brief_summary>
	<brief_title>Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours</brief_title>
	<detailed_description />
	<mesh_term>Cediranib</mesh_term>
	<mesh_term>Saracatinib</mesh_term>
	<criteria>Written consent Cancer diagnosis &amp; stage Patients for whom no standard therapy exists World Health Organization (WHO) performance status 02 One or more measurable lesions Prostate cancer Untreated unstable brain or meningeal metastases Specific laboratory ranges Pregnant or breastfeeding women Any evidence of severe or uncontrolled diseases Participation in other trials within 30 days</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Tumour</keyword>
	<keyword>Advanced Solid Tumour</keyword>
	<keyword>Lung Cancer</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Cholangiocarcinoma</keyword>
	<keyword>Colon Cancer</keyword>
	<keyword>Gastric Cancer</keyword>
	<keyword>Choriocarcinoma</keyword>
	<keyword>Liver Cancer</keyword>
	<keyword>Myeloma</keyword>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Pancreatic Cancer</keyword>
	<keyword>Peritoneal Cancer</keyword>
</DOC>